A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma

By Hamid Omid   Ilaria Robert   Garbe Claus   Wolter Pascal   Maio Michele   Hutson Thomas E.   Arance Ana   Lorigan Paul   Lee Jeeyun   Hauschild Axel   Mohr Peter   Hahka-Kemppinen Marjo   Kaiser Christopher   Turner P. Kellie   Conti Ilaria   Grob Jean-Jacques  

Cancer, Vol. 120, Iss. 13, 2014-07 ,pp. : 2016-2024

Blackwell Publishing

Access to resources Recommend Favorite

A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma

By Smylie Michael   Wong Ralph   Mihalcioiu Catalin   Lee Chris   Pouliot Jean-Francois  

Investigational New Drugs, Vol. 25, Iss. 2, 2007-04 ,pp. : 155-159

Springer Publishing Company

Access to resources Recommend Favorite

Safety of Efalizumab Therapy in Patients with Moderate to Severe Psoriasis: An Open-Label Extension of a Phase IIIb Trial

By Hamilton Tiffani  

Drug Safety, Vol. 31, Iss. 8, 2008-01 ,pp. : 715-726

Adis International

Access to resources Recommend Favorite

Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer

By Michael Michael   Gibbs Peter   Smith Robert   Godwood Alex   Oliver Stuart   Tebbutt Niall  

Investigational New Drugs, Vol. 27, Iss. 3, 2009-06 ,pp. : 253-261

Springer Publishing Company

Access to resources Recommend Favorite

A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response

By Rifkin Robert  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 714-722

Springer Publishing Company

Access to resources Recommend Favorite